Bruton's tyrosine kinase as anti-cancer drug target
Receptor protein tyrosine kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of the tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer cell survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.
1. A method of treating cancer, comprising:
a) providing:
i) a subject having cancerous cells, and
ii) an inhibitor of a gene encoding a variant of a cytoplasmic tyrosine kinase, wherein said variant comprises a Bruton's Tyrosine Kinase that is at least 95% identical with SEQ ID NO. 3 and an amino-terminal extension thereof, and
b) treating said cells with said inhibitor, such that said treating reduces proliferation of said cancer cells.
2. The method of claim 1 , wherein said inhibitor comprises an interfering RNA.
3. The method of claim 1 , wherein said treating takes place in vitro.
4. The method of claim 1 , wherein said treating takes place in vivo.
5. The method of claim 1 , wherein said cancerous cells are breast cancer cells.
6. The method of claim 1 , wherein said amino terminal extension is a sequence of 34 amino acids.
7. A method of treating cancer, comprising:
a) providing:
i) a subject having cancerous cells, and
ii) an inhibitor of a gene encoding a variant of a cytoplasmic tyrosine kinase, wherein said variant comprises a Bruton's Tyrosine Kinase and an amino-terminal extension thereof, wherein said amino terminal extension is at least 95% identical with the amino terminal extension of SEQ ID NO. 3, and
b) treating said cells with said inhibitor, such that said treating reduces proliferation of said cancer cells.
8. The method of claim 7 , wherein said inhibitor comprises an interfering RNA.
9. The method of claim 7 , wherein said treating takes place in vitro.
10. The method of claim 7 , wherein said treating takes place in vivo.
11. The method of claim 7 , wherein said cancerous cells are breast cancer cells.
12. The method of claim 7 , wherein said amino terminal extension is a sequence of 34 amino acids.